Fundz Deep Dive

Everything you need to win Capstan Therapeutics — in one platform.

Who to reach, what to say, and why now on Capstan Therapeutics — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.

Get the full Deep Dive on Capstan Therapeutics — free.

One free Deep Dive, emailed to you. No spam; unsubscribe anytime.

Ready now? Choose your plan · Request a demo · Sign in

Engage writes the reply

Grounded in signals no one else has — tuned to their persona.

Signals no one else has

UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.

Verified contact + click-to-call

The decision-maker’s email and mobile — dial in-browser.

Capstan Therapeutics, Inc. raised $175M in a Series B financing led by RA Capital Management to advance in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles

PRIVATEMar 20, 2024•about 2 years ago

Amount Raised

$175 Million

Round Type

series b

San DiegoBiotechnologyHealth CareTherapeutics

Investors

Vida VenturesPolaris PartnersPfizer VenturesOrbi MedNovartis Venture FundLeaps By BayerEli Lilly And CompanyBristol Myers SquibbAlexandria Venture InvestmentsSofinnova InvestmentsPerceptive AdvisorsMubadala CapitalJohnson & Johnson Innovation JjdcForbionRa Capital Management

Description

Capstan Therapeutics, Inc. announced the successful closing of a $175M oversubscribed Series B financing. The financing was led by RA Capital Management, with participation from new investors Forbion, Johnson & Johnson Innovation - JJDC, Mubadala Capital, Perceptive Advisors, and Sofinnova Investments, as well as existing investors Alexandria Venture Investments, Bristol Myers Squibb, Eli Lilly and Company, Leaps by Bayer, Novartis Venture Fund, OrbiMed, Pfizer Ventures, Polaris Partners, and Vida Ventures.

Company Information

Company

Capstan Therapeutics

Location

San Diego, California, United States

About

Capstan is a biotechnology company with a mission to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. The core platform technology comprises proprietary targeted lipid nanoparticles (tLNPs) that are composed of LNPs conjugated with a recombinant protein binder, such as a monoclonal antibody. tLNPs are designed to deliver payloads, including mRNA or gene editing tools, capable of reprogramming specific cell types in vivo. The platform technology has the potential to generate transformative therapies with possible applications across a broad range of disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. For more information, please visit www.capstantx.com and follow us on LinkedIn.

Related People

Suggested for you

1 contact

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for Capstan Therapeutics's next move

Learn about Strategic plan

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Watching Capstan Therapeutics? See every signal — funding, hires, M&A, contracts, sentiment.

Request a demo Choose your plan